Navita L. Mallalieu

Low immunogenicity of tocilizumab in patients with rheumatoid arthritis

Gerd R Burmester, Ernest Choy, Alan Kivitz et al. · Annals of the Rheumatic Diseases · 2016 · 101 citations · Full text

Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers

Navita L. Mallalieu, Erica Winter, Scott Fettner et al. · Antimicrobial Agents and Chemotherapy · 2020 · 50 citations · Full text

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis

Nicolino Ruperto, Hermine I. Brunner, Athimalaipet V Ramanan et al. · Lara D. Veeken · 2021 · 34 citations · Full text

Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

Navita L. Mallalieu, Sunethra Wimalasundera, Joy Hsu et al. · Pediatric Rheumatology · 2019 · 24 citations · Full text

RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: Synthesis and biological evaluation

Lee McDermott, Mary Ellen Simcox, Brian Higgins et al. · Bioorganic & Medicinal Chemistry · 2005 · 21 citations · Full text

Molecular Pharmacology, Biochemistry, Medicine +8